As heart failure patients, the TAVI population studied already is recommended to be treated with an SGLT2 inhibitor, noted ...

Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also ...

Guggenheim initiated coverage on shares of Assembly Biosciences (NASDAQ:ASMB – Free Report) in a report released on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $31.00 ...

The developer of a spray-based erectile dysfunctional treatment, LTR Pharma has found a pre-approval route to the US market.

Assembly Biosciences (NASDAQ:ASMB – Get Free Report)‘s stock had its “neutral” rating reiterated by stock analysts at HC ...

According to Straits Research, The Mold Inhibitors Market size was valued at USD XX Billion in 2023 to USD 3.03 Billion by ...

US regulators have once again declined to approve Hengrui Pharmaceuticals' (SHA: 600276) PD-1 inhibitor camrelizumab, further delaying the drug's entry into the American market.

Omeros has announced that the activation of clinical trial sites for patient enrolment is now in progress for its Phase III ...

The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Omeros (OMER) reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart ...